Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation o...
Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study
About this item
Full title
Author / Creator
Johnson, Julie A., PharmD , Boerwinkle, Eric, PhD , Zineh, Issam, PharmD , Chapman, Arlene B., MD , Bailey, Kent, PhD , Cooper-DeHoff, Rhonda M., PharmD, MS , Gums, John, PharmD , Curry, R. Whit, MD , Gong, Yan, PhD , Beitelshees, Amber L., PharmD, MPH , Schwartz, Gary, MD and Turner, Stephen T., MD
Publisher
New York, NY: Mosby, Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Mosby, Inc
Subjects
More information
Scope and Contents
Contents
Background Selection of antihypertensive therapy is often empiric, and use of genetic information to guide drug therapy selection holds future promise. Trial design The objective of this trial is to identify the genetic determinants of the antihypertensive and adverse metabolic responses to a thiazide diuretic (hydrochlorothiazide), a β-blocker (at...
Alternative Titles
Full title
Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671287
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671287
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2008.11.018
